



PARKINSON STUDY GROUP
CONFLICT-OF-INTEREST GUIDELINES

ETHICAL AND CONFLICT-OF-INTEREST GUIDELINES FOR MEMBERS OF THE
PARKINSON STUDY GROUP (PSG)
(AS APPROVED BY THE PSG ON APRIL 29, 1990,
AND AMENDED ON FEBRUARY 27, 1993, MAY 4, 1996, and
DECEMBER 31, 2005)

Members of the PSG should maintain the highest personal and professional standards in conducting clinical trials and research. Real and perceived conflict-of-interest must be avoided.

To these ends, we agree that:

1. PSG members shall not in any way or manner benefit financially as a result of their participation in and knowledge of PSG studies. In particular, PSG members agree not to own or trade in the equity of a company whose drugs or products are being investigated by the PSG ("involved company"). PSG members further agree not to inform or influence relatives, friends or others in financial transactions regarding the "involved company". PSG members agree not to accept compensation arrangements in which the value of the compensation could be affected by the outcome of the PSG studies in which they are participating. In addition, members participating in a PSG clinical trial agree not to hold a financial interest in the study drug or related drugs or products including, but not limited to, a patent, trademark, copyright or licensing arrangement.
2. PSG members have an obligation to act in the public interest and should be willing to educate the scientific and lay communities. PSG members agree that such practices are permitted provided there is no disclosure of confidential information or any potential for jeopardizing the successful outcome of any clinical trial which is in progress.
3. PSG members agree not to serve as paid consultants to an "involved company" or to any individual or entity acting on behalf of the involved company in relation to the study drug or related drugs or products of the company during the period of the clinical trial, except as an activity or consultation under the auspices of the PSG. No personal compensation shall accrue to the PSG member for these activities. All educational, consulting and other payments from "involved companies" relating to the study drug or related drugs must be directed to a public charity, a scientific society, the member's department university or hospital (an academic account administered by the PSG member

is acceptable) or to the PSG. Such activities and payments must be disclosed to the Executive Committee via annual Conflict of Interest reports.

4. Certain activities with “involved companies” are permitted, however payments received by the PSG member must be disclosed to the Executive Committee via annual Conflict of Interest reports. These include serving as an educator in CME accredited programs sponsored by an “involved company” or participating in consulting or research activities supported by the “involved company” which are unrelated to the drug or product under evaluation by the PSG.

5. For the Principal Investigator, Co-Principal Investigator, Steering Committee members, Coordination and Biostatistics Center staff, the Executive Committee and members of the study Writing (Publication) Committee (if any), these ETHICAL AND CONFLICT-OF-INTEREST GUIDELINES will apply from the time of recruitment of subjects into a study until the latter of one month following publication of a manuscript reporting the primary endpoint of the study, or when the Steering Committee for the study determines that no such publication will occur. For site investigators, site coordinators and site support staff, these ETHICAL AND CONFLICT OF INTEREST GUIDELINES will apply until one month after the first public report of the primary results of the study, including in abstract form. This will be binding for all PSG members including those who might leave the study, for any reason, prior to its completion.

6. In these GUIDELINES, a PSG member is defined as an investigator, coordinator, data processor, statistician, consultant, or any other person involved with and privy to information regarding PSG studies.

ADDENDUM (Approved February 27, 1993)

1. Members of the PSG should insist on full and meaningful disclosure of financial support for educational events to which they are invited to participate.

2. Members of the PSG should fully disclose their research support and any significant financial interest with manufacturer(s) of commercial products related to the topic of their presentation for education events in which they participate.